InspireMD, Inc. announced its financial and operating results for the second quarter and six months ended June 30, 2025, on August 5, 2025. For Q2 2025, total revenue increased by 2.3% to $1.778 million from $1.739 million in Q2 2024, driven by continued adoption in existing markets.
Gross profit for Q2 2025 decreased by 5.4% to $313,000, while total operating expenses increased significantly by 55.2% to $13.332 million. This increase was primarily due to higher salaries and share-based compensation tied to U.S. sales force expansion, CGuard Prime launch preparation, and development activities for SwitchGuard NPS.
The net loss for Q2 2025 totaled $13.151 million, or $0.26 per share, compared to a net loss of $7.909 million, or $0.22 per share, for the same period in 2024. As of June 30, 2025, cash and cash equivalents and marketable securities were $19.374 million.
CEO Marvin Slosman highlighted the execution of significant milestones, including U.S. approval and commercial rollout of CGuard Prime, and the addition of $58 million in gross proceeds to the balance sheet. The company is focused on scaling with discipline to establish its technology as the standard of care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.